Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. specializes in the production of active pharmaceutical ingredients (APIs) and intermediates, primarily serving the Chinese market with a growing export presence in Europe and North America. The company's competitive position is bolstered by its strong gross margin of 69.8% and low debt levels, allowing for significant operational flexibility.
Zhejiang Cheng Yi generates revenue primarily through the sale of APIs and intermediates to pharmaceutical companies, leveraging its high gross margin and low debt to maintain competitive pricing. The company benefits from economies of scale and a strong reputation for quality, which enhances customer loyalty and pricing power.
Regulatory approvals for new APIs
Changes in pharmaceutical pricing policies in China
Export demand fluctuations in Europe and North America
New contract manufacturing agreements
Regulatory changes in drug approval processes
Technological disruption in pharmaceutical manufacturing
Emerging generic competitors in the API space
Price competition from larger multinational pharmaceutical companies
Potential liquidity risks if cash flow declines
Minimal financial risk due to low debt levels
moderate - As a pharmaceutical company, demand is relatively inelastic, but economic downturns can affect spending on healthcare.
Minimal impact as the company has low debt levels; however, rising rates could affect overall market valuations.
minimal - The company has a debt/equity ratio of 0.03, indicating low reliance on external financing.
growth - Investors may be drawn to the company's revenue growth potential and high margins.
moderate - The stock has shown some volatility with a 1-year return of -1.3%.
